製品番号: HY-156432

ALK-IN-26

カスタマーレビュー

Based on 1 Customer Validation

ALK-IN-26 is an ALK inhibitor with IC₅₀ value of 7.0 μM for ALK tyrosine kinase. ALK-IN-26 has good pharmacokinetic properties and blood-brain barrier (BBB) permeability. ALK-IN-26 can induce apoptosis, autophagy and necrosis. ALK-IN-26 can be used in glioblastoma studies.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.87%
CAS 番号: 2447607-85-2
分子式: C₂₄H₂₃NO₃S
分子量:405.51

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

ALK-IN-26 構造式

CAS 番号: 2447607-85-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

mTOR アイソフォーム固有の製品をすべて表示 :

PARP アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
GL261	IC₅₀	1.35 μM Compound: 4a	Anti-proliferative activity against mouse GL261 cells assessed as cell viability incubated for 2 hrs by CCK8 assay Anti-proliferative activity against mouse GL261 cells assessed as cell viability incubated for 2 hrs by CCK8 assay	[PMID: 37861443]
U-87MG ATCC	IC₅₀	7.25 μM Compound: 4a	Anti-proliferative activity against human U-87 MG cells assessed as cell viability incubated for 2 hrs by CCK8 assay Anti-proliferative activity against human U-87 MG cells assessed as cell viability incubated for 2 hrs by CCK8 assay	[PMID: 37861443]

体外実験

ALK-IN-26 (0.5-2 μM, 24 h) can inhibit the activity of ALK in GL216 cells^[1].
ALK-IN-26 (0.5-2 μM, 24 h) can reduce the expression of mTOR protein in GL216 cells ^[1].
[1].
ALK-IN-26 (0.5-2 μM, 24 h) significantly decreases p-ERK1/2 protein level and enhances p-JNK protein level in GL261 and U87MG cells, while has little effect on p-AKT and p-STAT3 protein levels^[1].
ALK-IN-26 (0.5μM-2.0 μM, 24h) can induce autophagy in GL261 cells^[1].
ALK-IN-26 (0.5 μM-0.5 μM, 24-72 h) increases the protein levels of cleaved-PARP (c-PARP) and cleaved-caspase-3 (c-caspase 3) in GL261 cells^[1].
ALK-IN-26 (0.5 μM-2μM, 24-72 h) induces apoptosis in GL261 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

GL261
Concentration:

0.5 μM, 1.0 μM, 2.0 μM
Incubation Time:

24 h, 48 h, 72 h
Result:

Induced apoptosis of glioblastoma in a concentration- and time-dependent manner, and caused the cells (24.5%) entered the S phase but barely proceeded to the G2/M phase when treated with 1 μM for 72 h.

Cell Viability Assay^[1]

Cell Line:

GL216, U87MG, Hela
Concentration:

0.5 μM, 1.0 μM, 2.0 μM, 5 μM, 10 μM for GL216 and U87MG cells 5 μM, 10 μM, 20 μM, 40 μM, 80 μM, 160 μM for Hela cells
Incubation Time:

24 h, 48h, 72h
Result:

Inhibited the activity of GL216 cells with the inhibition rate of cells at 80% when incubated with 2 μM for 72 h and inhibited U87MG cells viability with a dose- and time-dependent manner, while showed limited inhibition on Hela cells, even at 160 μM, the inhibition rate is less than 50%.
Can inhibit the activity of ALK tyrosine kinase with a dose-dependent manner.

Cell Autophagy Assay^[1]

Cell Line:

GL261
Concentration:

0.5 μM, 1.0 μM, 2.0 μM
Incubation Time:

24 h
Result:

Induced autophagy death in glioblastoma cells.

体内実験

ALK-IN-26 (5 mg/kg, i.v., single dose) has pharmacokinetic properties in male C57BL6/J mice^[1].
ALK-IN-26 is (20 mg/kg, i.p., single dose) able to penetrate the blood-brain barrier in male C57BL6/J mice^[1].

Pharmacokinetic parameters of C57BL6/J in male rats (n = 3) ^[1]

Pharmacokinetic property	T_1/2(h)	T_max(h)	C_max (ng/mL)	AUC_(0-8) (h*ng/mL)	AUC_(0-∞) (h*ng/mL)	MRT_(0-8) (h)	MRT_(0-∞) (h)	V_∞ (L/kg)	V₂ (L/kg)	bioavailablity F (%)
i.v.(5mg/kg)	1.13	0.08	1978.21	884.88	924.56	0.63	0.84	4.59	8.89	38.40
i.p.(5mg/kg)	3.55	0.58	117.57	339.79	420.50	2.25	4.60	/	/	/

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6J mice^[1]
Dosage:

5 mg/kg
Administration:

Intravenous injection (i.v.), Single dose
Result:

Could be rapidly absorbed (Tmax = 0.58 h) with an acceptable half-life (T1/2 = 3.55 h) and bioavailability (F = 38.4%).

Animal Model:

Male C57BL/6J mice^[1]
Dosage:

20mg/kg
Administration:

Intraperitoneal injection (i.p.), Single dose
Result:

Could enter the body at concentrations up to 2.7μmol/kg (after 2 h administration at 20 mg/kg) and penetrate the blood-brain barrier.

化学情報

CAS 番号 2447607-85-2
性状 Solid
分子量 405.51
分子式 C₂₄H₂₃NO₃S
Color White to off-white
SMILES

O=S(C1=CC=C(C)C=C1)(N2C=C(CC3=CC(C)=C(O)C(C)=C3)C4=C2C=CC=C4)=O
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 125 mg/mL (308.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4660 mL

12.3302 mL

24.6603 mL

5 mM

0.4932 mL

2.4660 mL

4.9321 mL

10 mM

0.2466 mL

1.2330 mL

2.4660 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (283 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Feng L, et al. Synthesis and Bioevaluation of 3-(Arylmethylene) indole Derivatives: Discovery of a Novel ALK Modulator with Antiglioblastoma Activities[J]. Journal of Medicinal Chemistry, 2023. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4660 mL	12.3302 mL	24.6603 mL	61.6508 mL
	5 mM	0.4932 mL	2.4660 mL	4.9321 mL	12.3302 mL
	10 mM	0.2466 mL	1.2330 mL	2.4660 mL	6.1651 mL
	15 mM	0.1644 mL	0.8220 mL	1.6440 mL	4.1101 mL
	20 mM	0.1233 mL	0.6165 mL	1.2330 mL	3.0825 mL
	25 mM	0.0986 mL	0.4932 mL	0.9864 mL	2.4660 mL
	30 mM	0.0822 mL	0.4110 mL	0.8220 mL	2.0550 mL
	40 mM	0.0617 mL	0.3083 mL	0.6165 mL	1.5413 mL
	50 mM	0.0493 mL	0.2466 mL	0.4932 mL	1.2330 mL
	60 mM	0.0411 mL	0.2055 mL	0.4110 mL	1.0275 mL
	80 mM	0.0308 mL	0.1541 mL	0.3083 mL	0.7706 mL
	100 mM	0.0247 mL	0.1233 mL	0.2466 mL	0.6165 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

ALK-IN-26

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

mTOR アイソフォーム固有の製品をすべて表示

PARP アイソフォーム固有の製品をすべて表示

Caspase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

ALK-IN-26 関連分類

HY-156432 関連分類